Evidence map›Paper›PMID 29464307›Full record

ReviewDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2018

[Pathology of early stage cancer of the gastrointestinal tract : Definition, principles and diagnosis].

B Märkl, B Martin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

B MärklInstitut für Pathologie, Klinikum Augsburg, Stenglinstraße 2, 86157, Augsburg, Deutschland. bruno.maerkl@klinikum-augsburg.de.
B MartinInstitut für Pathologie, Klinikum Augsburg, Stenglinstraße 2, 86157, Augsburg, Deutschland.
University Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly stage cancers of the gastrointestinal tract are malignant tumors that are eligible for local therapy regimens and show an excellent prognosis.

objectiveThis article explains the histopathological aspects of the various diseases that are covered by this topic.

methodsOrgan-preserving therapies are discussed according to their locations and under consideration of the current guidelines and the relevant literature.

resultsThe exact histopathological evaluation of early cancers of the gastrointestinal tract is of crucial importance. It is the essential basis for all further therapy decisions. In most cases, an option for a local resection is given. In comparison to partial or complete organ resections, local resection is associated with a significantly decreased morbidity and reduced length of hospital stays; however, it must be ensured that local therapies do not become responsible for increased rates of tumor recurrence and progression. Therefore, an optimal risk estimation based on a sophisticated histopathological classification is mandatory. This includes the evaluation of the infiltration depth, grading, lymphovascular invasion and resection margins.

conclusionMolecular analyses have not yet entered clinical practice. The only exceptions are investigations to detect hereditary diseases. The exact histopathological diagnostic of early gastrointestinal cancers is the basis of an effective and organ-preserving therapy.

Indexed as

Gastrointestinal NeoplasmsHumansPrognosisClassificationHistopathologyLocal resectionLymphovascular infiltrationRisk stratification

Identifiers

PMID29464307
OpenAlexW2791688732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.